Search Results 131-140 of 17254 for peptide combinations

1. Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   This is a phase 1, multi-center, single-arm, open-label study evaluating the safety, tolerability, and anti-myeloma activity of ACTR087 (an autologous T cell ...

2. Combination of Serabelisib and Insulin Suppressing Diet in Subjects With Advanced Solid Tumors with PIK3CA Mutations - Mayo Clinic

   Combination of Serabelisib and Insulin Suppressing Diet in Subjects With Advanced Solid Tumors with PIK3CA Mutations. Print details. Share; Facebook · Twitter.

3. Study to Determine the Safety and Effectiveness of CLS-TA in Combination with an Intravitreal Anti-VEGF Agent in Subjects with Retinal Vein Occlusion - Mayo Clinic

   Study to Determine the Safety and Effectiveness of CLS-TA in Combination with an Intravitreal Anti-VEGF Agent in Subjects with Retinal Vein Occlusion · Overview.

4. A Study to Evaluate CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma - Mayo Clinic

   CB-839 HCl and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as ...

5. Semaglutide (subcutaneous route) - Side effects & dosage - Mayo Clinic

   Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide injection is also used together with diet and exercise to help lose weight ...

6. Science Saturday: Research helps play it safe in the ICU - Mayo Clinic News Network

   To combat these infections, physicians can choose from several antibiotics, and often will use a combination of drugs until they are certain of what is causing ...

7. Preparing for nuclear medicine therapy - Mayo Clinic

   A member of the nuclear medicine therapy team talks with a woman before she begins intravenous peptide receptor radionuclide therapy (PRRT). This type of ...

8. Stomach Cancer Clinical Trials - Mayo Clinic Research

   ... combinations in patients with locally advanced unresectable or metastatic G/GEJ cancer (hereafter referred to as gastric cancer). Two cohorts will be ...

9. Clinical trials - Oncology (Medical)

   The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with respect to OS. All ...

10. ADG126 In Combination With Pembrolizumab In Patients With Advanced/Metastatic Solid Tumors - Mayo Clinic

    This is a Phase 1b/2, open-label, dose escalation study to evaluate the safety, tolerability, PK, and immunogenicity of ADG126-pembrolizumab combination ...